PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23288881-6	2013	Switching to EZ/S provided significantly greater reductions in LDL-C versus statin doubling and significantly greater achievement of LDL-C targets versus statin doubling or switching to rosuvastatin.	Ezetimibe, Simvastatin Drug Combination	13-17	component of oligomeric golgi complex 2	Homo sapiens	63-68	
23288881-6	2013	Switching to EZ/S provided significantly greater reductions in LDL-C versus statin doubling and significantly greater achievement of LDL-C targets versus statin doubling or switching to rosuvastatin.	Ezetimibe, Simvastatin Drug Combination	13-17	component of oligomeric golgi complex 2	Homo sapiens	133-138	
28291866-3	2017	Objective: To assess the safety and clinical efficacy of achieving a very low (<30 mg/dL) level of LDL-C at 1 month using data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial.	Ezetimibe, Simvastatin Drug Combination	171-178	component of oligomeric golgi complex 2	Homo sapiens	102-107	
21497705-3	2011	Data to support the LDL-C lowering efficacy of ezetimibe/simvastatin (EZE/SMV) outside of controlled clinical studies are currently lacking.	Ezetimibe, Simvastatin Drug Combination	70-77	component of oligomeric golgi complex 2	Homo sapiens	20-25